Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2641 to 2655 of 8914 results

  1. Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable [ID6736]

    Awaiting development Reference number: GID-TA11964 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]

    Awaiting development Reference number: GID-TA11336 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Itepekimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6547]

    Awaiting development Reference number: GID-TA11716 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265]

    Awaiting development Reference number: GID-TA11307 Expected publication date:  06 January 2027

    Technology appraisal guidance
    Awaiting development

  5. Eneboparatide for treating chronic hypoparathyroidism [ID6532]

    Awaiting development Reference number: GID-TA11688 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Camizestrant as an add-on to palbociclib and abemaciclib for untreated hormone receptor-positive HER2-negative metastatic breast cancer with an ESR1 mutation [ID6535]

    Awaiting development Reference number: GID-TA11687 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158]

    Awaiting development Reference number: GID-TA11094 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Apraglutide for treating short bowel syndrome [ID6533]

    Awaiting development Reference number: GID-TA11695 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Capsule sponge tests for detection of Barrett's oesophagus and early-stage oesophageal cancer and surveillance of Barrett's oesophagus [ID6683]

    In development Reference number: GID-TA11960 Expected publication date:  24 February 2027

    Technology appraisal guidance
    In development

  10. Sugemalimab for consolidation treatment of locally advanced or unresectable non-small-cell lung cancer after chemoradiotherapy [ID6737]

    Awaiting development Reference number: GID-TA11965 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Sacituzumab govitecan with pembrolizumab for untreated metastatic non-small-cell lung cancer with a PD-L1 expression of 50% or more [ID6739]

    Awaiting development Reference number: GID-TA11880 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Fenfluramine for treating seizures caused by CDKL5 deficiency disorder in people 1 year and over [ID6740]

    Awaiting development Reference number: GID-TA11966 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Dronabinol for treating muscle spasticity in multiple sclerosis after 2 treatments [TSID10638]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment [ID3753]

    In development Reference number: GID-TA10620 Expected publication date:  12 June 2026

    Technology appraisal guidance
    In development

  15. Pulmonary sarcoidosis: infliximab (ES2)

    Summary of the evidence on infliximab for treating pulmonary sarcoidosis to inform local NHS planning and decision-making

    Evidence summary
    Published
    20 December 2016